Financials
Financial year 2025
JOLYPHARMA from Riemst, company number BE0473899537, closed financial year 2025 with a result of € 93,466 after tax. For that financial year JOLYPHARMA recorded a gross margin of € 169,801 and equity of € 952,385. Compared with financial year 2024, the result moved from € 104,953 to € 93,466. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 12, 2026.
€ 952,385
▲ 11% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 93,466
▼ 11% vs 2024
Profit after tax over the fiscal year.
€ 235,737
▲ 17% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 890,385.
People and assets in 2025
€ 170
▲ 4% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 32,039
▼ 19% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 163,472
▼ 14% vs 2024
€ 27,481 is repaid this year. At this pace the long-term loan is gone in ≈ 6 years.
€ 75,097
▲ 6% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 1,672
▼ 92% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 166,256 | € 146,967 | € 186,564 | € 169,801 | ▼ 9% |
| Profit after taxes | € 93,775 | € 80,446 | € 104,953 | € 93,466 | ▼ 11% |
| Equity | € 673,520 | € 753,966 | € 858,919 | € 952,385 | ▲ 11% |
| Total debts | € 363,640 | € 292,220 | € 293,454 | € 249,329 | ▼ 15% |
| Cash | € 176,976 | € 162,645 | € 202,176 | € 235,737 | ▲ 17% |
| Land & buildings | € 489,764 | € 466,200 | € 443,183 | € 418,152 | ▼ 6% |
| Retained profit | € 611,520 | € 691,966 | € 796,919 | € 890,385 | ▲ 12% |
| Bank debt | € 243,606 | € 217,270 | € 190,566 | € 163,472 | ▼ 14% |
| Balance sheet total | € 1,037,160 | € 1,046,186 | € 1,152,373 | € 1,201,714 | ▲ 4% |
Key figures of JOLYPHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to JOLYPHARMA?
What happened at JOLYPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Liberto Rutten stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 93,466 (▼ 11% vs 2024). filed late Source: NBB ↗
- Liberto Rutten became a director. NBB
- New establishment in Riemst. KBO
- Start of the company according to the CBE. KBO
In short
From € 93,775 profit in 2022 to € 93,466 profit in 2025.
Paid € 179,876 in corporate taxes since 2022.
Best year ever: 2024, with € 104,953 profit.
Management
Directors
According to the 2025 annual accounts
Liberto Rutten
Director
since 2023 · until 2029
Establishments
Establishment units
Physical locations of this company
Maastrichtersteenweg 180
3770 Riemst
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0473.899.537
- VAT number
- BE 0473.899.537
- Registered office
- Maastrichtersteenweg 180, 3770 Riemst
- Names & denominations
- JOLYPHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 24 January 2001
- Peppol
- Active · Active since 18 Nov 2025
- Contact
- [email protected]
- Activities · NACE
Detailhandel in farmaceutische producten
Apothekers